XML 32 R22.htm IDEA: XBRL DOCUMENT v3.19.2

Major Customers, Partnerships and Strategic Alliances (Tables)

6 Months Ended

Jun. 30, 2019

Kite Pharma Inc

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenues Recognized under Agreement

Revenues recognized under the agreement for the three and six months ended June 30, 2019 and 2018 were as follows (in thousands):

	Three Months Ended June 30,								Six Months Ended June 30,
	2019				2018				2019				2018
Revenue related to Kite agreement:
Recognition of upfront fee	$	6,227			$	5,953			$	12,386			$	5,953
Research services	2,833				1,562				4,986				1,562
Total	$	9,060			$	7,515			$	17,372			$	7,515

Pfizer SB-525

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenues Recognized under Agreement

Revenues recognized under the agreement for the three and six months ended June 30, 2019 and 2018 were as follows (in thousands):

	Three Months Ended June 30,								Six Months Ended June 30,
	2019				2018				2019				2018
Recognition of upfront fee related to Pfizer SB-525 agreement	$	4,635			$	8,183			$	1,595			$	15,841

Pfizer

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenues Recognized under Agreement

Revenues recognized under the agreement for the three and six months ended June 30, 2019 and 2018 were as follows (in thousands):

	Three Months Ended June 30,								Six Months Ended June 30,
	2019				2018				2019				2018
Recognition of upfront fee related to Pfizer C9ORF72 agreement	$	455			$	617			$	1,070			$	1,076

Bioverativ Inc

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenues Recognized under Agreement

Revenues recognized under the agreement for the three and six months ended June 30, 2019 and 2018 were as follows (in thousands):

	Three Months Ended June 30,								Six Months Ended June 30,
	2019				2018				2019				2018
Revenue related to Sanofi agreement:
Recognition of upfront fee	$	901			$	1,184			$	1,654			$	2,338
Research services	2,158				3,332				3,355				6,560
Total	$	3,059			$	4,516			$	5,009			$	8,898

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of contractual arrangements that involve two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Additionally, the element may include all other transactions of the entity categorized collectively, if such comparison of collaborative arrangements as a component of all transactions of the entity is desired.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 808
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434

+ Details

Name:	us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=sgmo_PfizerSB525Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=sgmo_PfizerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=sgmo_SanofiMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: